

TABLE 1. Isolates evaluated for virulence

Genomic group	Isolate	Notation in this study	Original source			
			Sample	Yr	Location	Disease
I	Nine Mile RSA493	NM	Tick	1935	Montana, US	NA <sup>a</sup> (acute; flu-like in humans)
	African RSA334	African	Human blood	1949	Central Africa	Acute; Congolese Red Fever
	Ohio 314 RSA270	Ohio	Cow's milk	1956	Ohio, US	Persistent
IV	MSU Goat Q177	Priscilla	Goat Cotyledon	1980	Montana, US	Abortion
	P Q173	P	Human heart valve	1979	California, US	Endocarditis
V	G Q212	G	Human heart valve	1981	Nova Scotia, Canada	Endocarditis
	S Q217	S	Human liver biopsy specimen	1981	Montana, US	Hepatitis
VI	Dugway 5J108-111	Dugway	Rodents	1958	Utah, US	NA

<sup>a</sup> NA, not applicable.

disease patients, and identified 30 genotypes in three monophyletic groups; an association between the plasmid type, some genotypes, and the nature of disease was observed (15). These monophyletic groups supported the early RFLP groups and placed groups I, II, and III in one monophyletic group; group IV in the second monophyletic group; and group V in the third monophyletic group. A comprehensive microarray-based whole-genome comparison by Beare et al. confirmed the relatedness of RFLP-grouped isolates and added two more genomic groups, VII and VIII (4). Differences in novel gene contents and pseudogenes may be factors in the variations in virulence seen among group I, IV, V, and VI isolates (5). It has been shown in an intraperitoneal (i.p.)-challenge guinea pig model that  $10^1$  organisms of the acute-disease-associated group I isolate Nine Mile RSA493 (NM) caused fever, but  $10^6$  chronic-disease-associated group IV isolate MSU Goat Q177 (Priscilla) organisms were required to induce fever (36).

In opposition to the theory of genotype/pathotype correlation, Stein and Raoult evaluated 28 human isolates and found that isolates bearing the QpH1 plasmid were present in both acute and chronic Q fever patients in France and that isolates without the QpH1 plasmid were able to cause acute disease (46). QpH1 plasmid-containing isolates have also been isolated from chronic-endocarditis patients (50). Several groups have speculated that host factors are primarily responsible for the outcome of infection with *C. burnetii*. Individual differences in immune function lead to varying sensitivity to infection and disease development. In this model, acute and chronic disease could be caused by organisms from the same isolate group, and chronic disease could develop because of compromised resistance of the host rather than as a consequence of a specific property of the pathogen. For example, human immunodeficiency virus infection is a risk factor for the development of chronic Q fever endocarditis (9, 29). Deficiencies in the host-specific cell-mediated immune response in Q fever patients have been associated with the suppression of monocyte and macrophage activities (25), and monocytes from chronic-Q fever patients have been shown to be defective in phagosome maturation and to have impaired *C. burnetii*-killing potential, regulated in part by elevated interleukin-10 (IL-10) expression (14). There is strong clinical evidence to support the role of increased host production of IL-10 in the development of both Q fever endocarditis and chronic fatigue syndrome (11, 12, 21, 39). A recent study suggested that chronic Q fever endocarditis may be associated with atypical M2 polarization and stimula-

tion of bacterial replication (7), but the pathogenic process that mediates this polarization was undefined.

The route of infection may also be an important determining factor in the manifestation of acute and chronic Q fever. La Scola et al. and Marrie et al. demonstrated that the route of infection and the size of the inoculum affected clinical illness and pathology associated with infection in mouse and guinea pig models (26, 33). Differences in the geographic distributions of the diseases have also been noted (32); in Nova Scotia, for example, the primary manifestation of acute Q fever is pneumonia (34), but in France it is hepatitis, possibly due to ingestion of raw milk and unpasteurized cheeses (51).

The pathogenicity of *C. burnetii* has been evaluated using guinea pigs, mice, and chicken embryos. Febrile response, splenomegaly, and mortality in guinea pigs; splenomegaly and mortality in mice; and mortality in chicken embryos are indicators of virulence for *C. burnetii*. The establishment of an aerosol model of *C. burnetii* infection in guinea pigs (43) provides a relevant model in which to test isolate virulence. Additionally, severe combined immunodeficient (SCID) mice are highly sensitive to the *C. burnetii* prototype (NM isolate) (1), and the 50% lethal dose ( $LD_{50}$ ) of NM in SCID mice was at least  $10^8$  times less than in wild type mice. We speculated that with these highly sensitive rodent models it may be possible to observe intra- and intergroup pathogenicity differences of *C. burnetii* isolates. To confirm whether SCID mice could be used to model isolate-specific virulence, we gave multiple infectious doses of a group IV Q fever isolate to immune-competent CB-17 and SCID mice (on the same background) to compare them with previously reported group I isolate (NM) infections (1). Eight isolates from four genomic groups (Table 1) were then evaluated for the ability to cause acute disease in SCID mouse i.p.-challenge and guinea pig aerosol challenge models. We hypothesized that isolates within the same genotypic group would cause similar diseases and that there would be a distinct difference in disease manifestations between isolate groups. Finally, we evaluated the potential of a vaccine composed of one *C. burnetii* isolate to protect guinea pigs against infection with an isolate from another group, since cross-protection between disparate isolate groups is a further indication of antigenic relatedness.

#### MATERIALS AND METHODS

**Animals.** The female 6- to 7-week-old CB-17/lcr-scld/scld (SCID) and wild-type CB-17/lcr<sup>+/+</sup> (CB-17) mice used in Japan were purchased from Japan

CLEA (Tokyo, Japan); A/J mice were purchased from Japan SLC (Shizuoka, Japan). A/J mice were used because they are considered more susceptible to *C. burnetii* than other inbred mouse strains (45). The female 6- to 8-week-old SCID and wild-type CB-17 mice used in the United States were purchased from Taconic (Hudson, NY). Female Hartley guinea pigs weighing approximately 350 to 450 g were purchased from Charles River Laboratories (Wilmington, MA).

All infected animals were housed in approved animal biosafety level 3 facilities, and immunodeficient mice were housed under sterile conditions. All animals used in this study were acclimated to the facility and assessment procedures during the week prior to infection to decrease stress-related abnormalities. Animal health was assessed daily by a veterinarian.

Mouse experiments performed in Japan adhered to the guidelines for animal experiments at Gifu University. The Texas A&M University Laboratory Animal Care Committee reviewed and approved the mouse and guinea pig research at Texas A&M University, and experiments were carried out in AAALAC-approved facilities in accordance with university and federal regulations.

*C. burnetii*. Eight *C. burnetii* isolates from four genomic groups (Table 1) were used. For the initial dose-effect experiment in Japan, *C. burnetii* MSU Goat Q177 (Priscilla), obtained from J. Kazar, Institute of Virology, Bratislava, Slovakia, was maintained in mice by passage in spleen homogenates at Gifu University. The spleen homogenates were stored at  $-80^{\circ}\text{C}$  until they were used. The absence of contamination with other pathogens was confirmed by direct staining (Giménez and Gram staining), detection of *Mycoplasma* DNA using a PCR *Mycoplasma* detection set (Takara, Shiga, Japan), and inoculation of the spleen homogenate into cell culture and SCID mice (independent experimental infection from the study described here). The bacterial dose was evaluated as the 50% tissue culture infectious dose (TCID<sub>50</sub>) in BGM cells (buffalo green monkey fibroblasts), the 50% infectious dose (ID<sub>50</sub>) in CB-17 mice, and the LD<sub>50</sub> in SCID mice. The TCID<sub>50</sub> was determined by detecting the bacteria 6 days after infection using immunofluorescence staining with anti-*C. burnetii* rabbit antiserum. The ID<sub>50</sub> was determined by detecting seroconversion (immunoglobulin G [IgG], >1:16) using indirect immunofluorescence. The LD<sub>50</sub> was determined as reported previously (1).

For all subsequent experiments, all of the *C. burnetii* isolates were maintained at the Texas A&M Health Science Center. The *C. burnetii* isolates were cultivated in embryonated chicken eggs, purified by gradient centrifugation as previously reported (19, 44, 53), and stored at  $-80^{\circ}\text{C}$  until they were used. The absence of contamination by other pathogens was confirmed as described above. *C. burnetii* was quantified by optical density (OD) (53), direct viable-particle count using the Live/Dead BacLight Bacterial Viability Kit (Molecular Probes, Eugene, OR), and quantitative real-time PCR (qPCR) using primers amplifying the *com1* gene (8) (see Table S1 in the supplemental material). The bacterial dose used for mouse infections was determined by qPCR; guinea pig doses were calculated using the OD.

**Experimental infection in mice.** (i) **Dose/effect experiment with the Priscilla isolate.** Six mice per group were used for the dose/effect experiment. SCID, CB-17, and A/J mice were inoculated i.p. with serial 10-fold dilutions of Priscilla ( $10^2$  to  $10^{-7}$  TCID<sub>50</sub> per animal) or sterile phosphate-buffered saline (PBS) (sham infection). SCID mice were observed for 112 days (16 weeks), and CB-17 and A/J mice were observed for 30 days.

(ii) **Genomic group comparison.** Four mice per group were used for the genomic group comparison. Each of eight *C. burnetii* isolates described in Table 1 ( $10^2$  genome copies/animal) or PBS was administered i.p. to SCID and CB-17 mice. Two independent infections were performed, and the mice were observed for 28 days (for all of the *C. burnetii* isolates in SCID and CB-17 mice) or until death (for four representative *C. burnetii* isolates in SCID mice).

Clinical signs were evaluated every 2 days by visual observation (ruffled fur, hunched-back appearance, and lethargy) and body weight measurement. Body weight changes were evaluated using a body weight index (BWI) derived as follows: BWI = relative body weight/mean relative body weight of the control group; relative body weight = body weight on day "x" of infection/body weight on the day of infection. Cachexia was diagnosed when a mouse was lethargic and had a BWI of less than 0.85. At necropsy, the spleen weight was measured as an indicator of *C. burnetii* infection (54), and tissues were collected. To quantify the growth of *C. burnetii*, DNA was extracted from spleen tissue and *C. burnetii com1* gene copies were detected by qPCR as previously described (8). The heart, lung, liver, spleen, kidney, and femur were formalin fixed, embedded in paraffin, sliced, and then prepared by hematoxylin-eosin staining and immunocytochemistry, as described previously (1, 8), to evaluate histopathologic changes and bacterial distribution in tissues. The degree of inflammation present in each tissue sample was scored numerically by the following system: 0, none; 1, mild; 2, moderate; 3, marked; 4, severe. IgG titers for phase I and II *C. burnetii* in the sera of CB-17 mice were measured by microimmunofluorescence as described elsewhere (1).

For cytokine assays, blood was collected from the lateral saphenous vein at 3, 7, 10, 14, and 21 days postinfection (p.i.) and via cardiac puncture at 28 days p.i. after euthanasia, and the group pooled sera were stored at  $-80^{\circ}\text{C}$  until they were used. Sixteen cytokines (IL-1 $\alpha$ , IL-1 $\beta$ , IL-2, IL-3, IL-4, IL-5, IL-6, IL-12p40, IL-12p70, IL-10, granulocyte-macrophage colony-stimulating factor, gamma interferon [IFN- $\gamma$ ], KC, macrophage inflammatory protein 1 $\alpha$  [MIP-1 $\alpha$ ], RANTES, and tumor necrosis factor alpha [TNF- $\alpha$ ]) were measured using the Bio-Plex cytokine assay system (Bio-Rad, Hercules, CA) following the manufacturer's protocol. The cytokine quantification assay was performed in duplicate for each sample. The cytokine levels of infected sera were evaluated as the induction values compared to the values of uninfected sera.

**Experimental infection in guinea pigs.** A chamber specially designed to deliver droplet nuclei directly to the alveolar spaces (College of Engineering Shops, University of Wisconsin, Madison), allowing the infection of multiple guinea pigs simultaneously and ensuring uniform infection within each challenge group (35, 43, 52), was used for all guinea pig infection studies. (i) Three guinea pigs per group were infected with low ( $10^2$ ), mid-level ( $10^4$ ), or high ( $10^6$ ) doses of one of the phase I *C. burnetii* isolates described in Table 1. Four negative control animals were sham infected with sterile PBS. Body weight, rectal temperature, and behavioral attitude were recorded, along with any abnormalities noted on thoracic auscultation and abdominal palpation. A rectal temperature of  $\geq 39.5^{\circ}\text{C}$  was defined as fever. The guinea pigs were observed for 28 days p.i. The spleens and livers were weighed at necropsy. Tissues were collected and formalin fixed for histopathologic evaluation. Serum was obtained from each animal for serologic testing. (ii) In a separate experiment, three guinea pigs per group were exposed to PBS or  $2 \times 10^6$  particle equivalents of NM, P, G, or Dugway. Daily assessment of these animals was performed as described above, and the organs were weighed at necropsy 14 days p.i. to detect splenomegaly and/or hepatomegaly. (iii) In the heterologous-protection study, guinea pigs were vaccinated twice with 40  $\mu\text{g}$  of formalin-inactivated group I (NM) or group V (S) *C. burnetii* in Freund's incomplete adjuvant or with adjuvant alone, with 2-week intervals between the vaccinations and infection. The animals were then infected with high doses of either NM or S. Three animals per group were separated into the following six groups: (a) nonvaccinated, NM infected; (b) nonvaccinated, S infected; (c) NM vaccinated, NM infected; (d) S vaccinated, S infected; (e) NM vaccinated, S infected; and (f) S vaccinated, NM infected. The guinea pigs were monitored for 14 days p.i. for development of fever and other clinical signs of illness.

Histopathologic samples were prepared by hematoxylin and eosin staining or by immunohistochemistry using a Vectastain ABC kit and a Vector NovaRed substrate kit (Vector Laboratories, Burlingame, CA) and in-house-generated rabbit anti-*C. burnetii* NM (3) and by counterstaining them with hematoxylin. All slides were evaluated in a blinded fashion. Serum samples collected at necropsy were tested by enzyme-linked immunosorbent assay for IgG titers against phase I *C. burnetii* NM antigen as previously described (43). Sera from uninfected guinea pigs were used as negative controls.

**Statistical analyses.** The results were expressed as means for each group and were compared using one- and two-way analysis of variance or Student's *t* test, as appropriate. Differences were considered significant at a *P* value of  $<0.05$ .

## RESULTS

***C. burnetii* Priscilla is infective and exhibits delayed virulence in SCID mice.** A detailed analysis of dose-effect in an immunocompromised-mouse model supported the previous study by Moos and Hackstadt that evaluated the ability of the Priscilla isolate to cause fever in i.p.-challenged guinea pigs (36). The infectious titer of the Priscilla isolate in the splenic homogenate used for the multiple-dose infection was  $2 \times 10^4$  TCID<sub>50</sub>/ml in BGM cells,  $2 \times 10^{9.3}$  ID<sub>50</sub>/ml in CB-17 mice, and  $2 \times 10^{10}$  LD<sub>50</sub>/ml in SCID mice (1 TCID<sub>50</sub> corresponded to  $10^{5.3}$  ID<sub>50</sub> in CB-17 mice and to  $10^6$  LD<sub>50</sub> in SCID mice). The LD<sub>50</sub> in CB-17 mice could not be determined because no CB-17 mice died from any infectious dose used in this study, and the ID<sub>50</sub> in SCID mice could not be determined due to lack of antibody production. The ID<sub>50</sub> in CB-17 mice and the LD<sub>50</sub> in SCID mice were similar, suggesting that SCID mice could be lethally infected with very few viable organisms.

Multiple-dose infection of SCID mice with the Priscilla iso-




FIG. 1. Average body weight changes in SCID mice (A) and CB-17 mice (B) infected with *C. burnetii* isolates during 28 days of infection. Body weights were significantly lower in SCID mice throughout the infection period and transiently in CB-17 mice infected with all isolates except Priscilla compared to PBS-injected controls ( $P < 0.05$ ).

late resulted in slow, progressive, and long-term-persistent disease. Clinical signs included ruffled fur, extremely distended abdomens, and death. Body weight loss, inactivity, and cachexia were not observed until a few days prior to death. Survival time ranged from 55 to 109 days p.i. Progression of clinical signs and survival times were dose dependent, with shorter times corresponding to higher infectious doses (see Table S2 in the supplemental material). Similar lesions were found in all of the SCID mice that died, most notably severe hepatosplenomegaly, and all organs had cellular infiltration, primarily macrophages containing bacteria. The severity of the lesions in infected SCID mice was not dependent on the *C. burnetii* challenge dose.

On the other hand, CB-17 and A/J mice displayed transitory clinical signs only after infection with the highest dose of Priscilla. Both mouse strains showed ruffled fur from 4 to 13 days p.i., but only A/J mice demonstrated transient body weight loss (data not shown). No other clinical signs were observed. At 28 days p.i., CB-17 and A/J mice had mild splenomegaly and seroconversion as evidence of infection (data not shown). Small granulomas were present in the spleen and liver, but bacterial antigen was not detectable by immunohistochemistry.

**Genomic-group-specific virulence in mice.** It was important to establish whether the results of infection seen with the Priscilla isolate and those previously noted with the NM isolate were genomic group specific (24). To determine this, the pathogenicities of multiple isolates were compared by delivering a single dose of eight *C. burnetii* isolates from four genomic groups (Table 1) to mice by i.p. injection. The infections were

initially compared in SCID and CB-17 mice sacrificed at 28 days p.i.

All *C. burnetii* isolates caused disease in SCID mice, with various clinical courses. There was no mortality during the 28-day infection period. Clinical signs, including significant body weight loss ( $P < 0.05$ ) and cachexia, summarized in Fig. 1A and in Fig. S1A in the supplemental material, were most apparent in mice infected with group I isolates, followed by those given group V, IV, and VI isolates. In CB-17 mice, only mild transient disease was noted, with minimal loss of body weight, in response to all isolates and noticeably ruffled fur with group I isolate infection (Fig. 1B).

Splenomegaly in response to infection was more severe in SCID than in CB-17 mice (Fig. 2A). The number of bacteria in the spleens was determined by qPCR (Fig. 2B), and consistently higher numbers of *comI* genes were detected in SCID than in CB-17 mice. SCID mice showed phylogenetic-group-characteristic spleen size and growth of bacteria. Splenomegaly was greatest in SCID mice with mild clinical disease infected with bacteria from groups IV and VI. However, the number of organisms in the spleen was greater in mice with severe clinical disease following infection with phylogenetic groups I and V. In CB-17 mice, splenic enlargement and numbers of bacteria increased with the severity of clinical disease. CB-17 mice displayed differences between infection with the *C. burnetii* isolates that caused acute disease (phylogenetic group I) and infection with the *C. burnetii* isolates that caused chronic disease (phylogenetic groups IV and V), but there was no difference between groups infected with isolates that caused chronic disease. All infected mice developed significant splenomegaly,




FIG. 2. Splenomegaly (A) and splenic bacterial loads (B) in mice at 28 days p.i. (A) All infected animals developed significant splenomegaly compared to controls, and infected SCID mice had significantly larger spleens than CB-17 mice ( $P < 0.05$ ). (B) Mice infected with group IV, V, and VI isolates had significantly fewer bacteria than those infected with group I isolates ( $P < 0.05$ ). \*,  $P < 0.05$ . The error bars indicate standard deviations.

but mice infected with group IV, V, and VI isolates had significantly fewer splenic bacteria than mice infected with group I isolates ( $P < 0.05$ ).

Evaluation of histopathology at 28 days p.i. revealed more lesions in SCID mice than in CB-17 mice (see Table S3 in the supplemental material). SCID mice showed histopathologic changes in all organs investigated. Group I isolates caused the most inflammation, followed by groups V, IV, and VI. The inflammatory-cell populations were similar in all groups and consisted of few neutrophils and numerous macrophages containing abundant intracytoplasmic bacteria. *C. burnetii* antigen was diffusely distributed in all organs examined. CB-17 mice had mild histopathologic changes in some organs, but even in the tissues with an inflammatory response, *C. burnetii* antigen was rarely detected.

**Circulating cytokines are altered in *C. burnetii*-infected CB-17 mice.** The variations in pathology and inflammation associated with these isolate group infections suggest differences in the immune responses. To expand on this observation, the serum levels of 16 cytokines and chemokines were measured. In CB-17 mice, serum cytokine levels differed between mice infected with group I isolates and those given isolates from other groups. Group I isolates induced persistently high cytokine secretion throughout the 28-day experiment; group IV and V isolates caused moderate cytokine secretion at the peak of clinical disease (7 to 14 days p.i.) (Fig. 3). After 14 days

p.i., group I isolates induced higher secretion of IL-3, IL-4, IL-6, IL-10, IL-12p40, IL-12p70, IFN- $\gamma$ , TNF- $\alpha$ , MIP-1 $\alpha$ , and RANTES than other groups. The KC and granulocyte-macrophage colony-stimulating factor levels of mice infected with group I isolates were higher than those in mice infected with other groups prior to 14 days p.i. Serum IL-1 $\alpha$ , IL-1 $\beta$ , IL-2, and IL-5 levels and eotaxin secretion were not increased during the infection period (data not shown).

**Lethal potentials of all genomic groups in SCID mice.** The lethal potentials of representative isolates from each phylogenetic group were investigated in SCID mice, and it was determined that all of the isolates evaluated could eventually lead to clinical illness and death in the immunodeficient model (see Fig. S1B in the supplemental material). Isolates that caused a long period of cachexia led to severe body weight loss in infected mice (see Fig. S2 in the supplemental material). A group I isolate (NM) induced the earliest and longest period of cachexia and, correspondingly, the most severe body weight loss. Mice infected with isolates from groups V (G) and VI (Dugway) had similar survival times, but those given group V isolates had longer periods of cachexia and more severe body weight loss than group VI-infected mice. Infection with group IV isolates (Priscilla and P) resulted in the shortest period of cachexia, and body weight loss was not observed until the terminal stage of infection. The survival time was shortest in mice challenged with group I isolates ( $32.0 \pm 0.8$  days), followed by those infected with groups V ( $36.0 \pm 0.0$  days), VI ( $35.5 \pm 1.0$  days), and IV ( $47.5 \pm 0.6$  days for P and  $77.3 \pm 2.8$  days for Priscilla). The probable cause of death was multiple-organ failure due to massive systemic infection.

The pathological changes in SCID mice at mortality were more advanced than those observed at 28 days p.i. (data not shown). The severity of inflammatory changes in the liver and spleen was similar in all groups of infected mice, but animals given group I isolates exhibited a greater degree of inflammation in the heart and lungs than those given group IV, V, and VI isolates. The extent of splenomegaly changed with survival time; however, the numbers of bacteria in the spleen were similar in all groups, suggesting that the number of bacteria ( $10^{10}$  genome copies/spleen) detected is the saturation point in SCID mice. *C. burnetii* antigen was diffusely distributed in all tissue sections.

**Genomic-group-specific outcome of acute Q fever pneumonia in the guinea pig aerosol model.** Aerosol challenge in the guinea pig provides a physiologically relevant model that simulates both the natural route of infection and common clinical presentations associated with human acute Q fever, making this a choice model for evaluating the comparative levels of virulence of different *C. burnetii* isolates, and thus, it was used in the logical progression of experiments after different levels of virulence were observed in mouse models of infection. Guinea pigs challenged with group I and V isolates developed significant fever in response to infection ( $P < 0.01$ ), whereas those given isolates from groups IV and VI were afebrile even at the highest challenge dose (Fig. 4).

Fever response, weight loss, and other clinical signs displayed a dose-dependent relationship in guinea pigs infected with the group I *C. burnetii* isolates African and Ohio, as has been described for the reference isolate in this group, NM (43). All animals that received African or Ohio organisms at a high




FIG. 3. Mean circulating cytokine levels in response to infection in CB-17 mice with different *C. burnetii* isolates. Isolates from genomic group I induced persistently high cytokine secretion with increased levels of IL-6, TNF- $\alpha$ , IL-12p40, IL-12p70, IFN- $\gamma$ , IL-3, IL-4, IL-10, MIP-1 $\alpha$ , and RANTES compared with other genogroups ( $P < 0.05$ ).  $\diamond$ , PBS;  $\square$ , NM;  $\triangle$ , African;  $\diamond$ , Ohio;  $\bullet$ , Priscilla;  $\blacklozenge$ , P;  $\blacksquare$ , G;  $\blacktriangle$ , S;  $\circ$ , Dugway.

dose died within 7 to 9 days p.i., as did two of three that received NM; lower infectious doses were not lethal. Gross lung consolidation and overall lack of normal body fat were noted on necropsy at 7 to 9 days p.i. in guinea pigs infected with the highest dose of organisms. Histologically, these animals had severe panleukocytic bronchointerstitial pneumonia with bronchial and alveolar exudates. Lung tissues from the surviving NM-infected guinea pig and those given the mid-level dose of group I organisms were evaluated at 28 days p.i. for comparison to animals infected with other isolates evaluated at this time, and they exhibited moderate multifocal lymphohistiocytic pneumonia with granuloma formation.

No significant fever or other overt clinical signs were noted in guinea pigs infected with group IV isolates. Mild lymphohistiocytic pneumonia was seen histologically at 28 days p.i. in animals given the highest dose of organisms.

Group V isolate-infected guinea pigs all developed fever when given the highest challenge dose, and dose-dependent temperature increases and other clinical signs were again noted, with no fever development, in those animals receiving the lowest dose of organism. Though auscultation confirmed respiratory compromise, none of the infections were lethal. At 28 days p.i., the lungs had mild to moderate lymphohistiocytic interstitial pneumonia and a few small granulomas.

No major clinical or pathological changes were noted in guinea pigs infected with the group VI isolate or in negative control animals. Table S4 in the supplemental material compares the severity of histopathologic changes in guinea pigs infected with high doses of *C. burnetii* isolates from each group

at 28 days p.i. Immunohistochemistry confirmed the presence of *C. burnetii* organisms, primarily in macrophages, in the lungs, livers, and spleens of infected animals.

Experimental guinea pigs in all dose groups for each isolate seroconverted by the time of euthanasia, with the exception of animals infected with high doses of NM, African, and Ohio necropsied at 1 week p.i. and low-dose Dugway-infected guinea pigs. The degree of seroconversion was dose dependent and varied among isolates (data not shown). No PBS-injected control animals seroconverted.

**Genomic-group-specific severity of hepatitis and splenomegaly in guinea pigs.** The doughnut granulomas common in human acute Q fever hepatitis (31) had not been previously described in animals experimentally infected with *C. burnetii* and were also not seen in the guinea pigs in this study. Mild hepatitis and severe hepatic lipidosis were noted at death 7 days p.i. in guinea pigs challenged with high doses of group I isolates, as had been previously reported for NM aerosol-infected guinea pigs (43). Tissue sections from the remaining NM-infected guinea pig and those infected with mid-level doses of the group I organisms were evaluated for comparison with animals infected with other isolates at 28 days p.i. and revealed vacuolization and degeneration of centrilobular hepatocytes, lymphocyte infiltration in periportal regions, and multiple small granulomas.

Group IV-infected guinea pigs also had periportal lymphocytic infiltration, as well as multiple granulomas of various sizes. The granulomas in Priscilla- and P-infected guinea pigs were more defined, with more histiocytic involvement than was




FIG. 4. Fever responses of guinea pigs to infection with high doses of *C. burnetii* isolates. The mean daily temperatures  $\pm$  standard errors of the mean ( $n = 3$ ) of animals infected with  $2 \times 10^6$  bacteria of each *C. burnetii* isolate. Temperatures of  $\geq 39.5^\circ\text{C}$  (black lines) were considered fever. The arrows indicate days on which death occurred in NM-, African-, and Ohio-infected groups.

seen in guinea pigs infected with group I isolates. Subjectively, of all animals necropsied from each isolate group, hepatic granulomas from those infected with P were the greatest in size and number.

The livers of guinea pigs infected with the group V isolates G and S contained a few small granulomas and mild to moderate infiltration of lymphocytes along portal tracts. The hepatic changes observed in guinea pigs infected with group V isolates suggested that isolates from this group are less hepatovirulent than group IV isolates but more so than group I isolates.

No hepatic granulomas or other significant pathological changes were noted in guinea pigs infected with the group VI isolate Dugway. Liver weights did not vary significantly within or between genomic groups.

There were no significant differences in spleen weights at 28 days p.i. within or between genomic or dose groups. Animals infected with all isolates examined at 14 days p.i. (NM, P, G, and Dugway) had significantly larger spleens than PBS-in-

jected control animals, and spleens from NM- and G-infected guinea pigs were significantly larger ( $P < 0.01$  and  $P < 0.05$ , respectively) than those of P- and Dugway-infected animals (see Fig. S3 in the supplemental material). Pathological findings included multiple small granulomas in the spleens of group I-infected guinea pigs; fewer small granulomas were occasionally noted in animals infected with group IV and V isolates.

**Heterologous protection of cross-vaccination and challenge in guinea pigs.** The infection studies described here illustrate that there is pathotype diversity between *C. burnetii* isolates from different genogroups, and they are consistent with phylogenetic studies cataloging distinct gene contents (4). We therefore strove to determine whether this diversity was great enough to affect the ability of vaccines to protect against infection. Guinea pigs were given group I (NM) or group IV (S) vaccine and cross-challenged to evaluate potential heterologous protection against high-dose infection. Nonvaccinated guinea pigs developed a noticeable fever response by day 5 p.i.,




FIG. 5. Heterologous vaccination and challenge in guinea pigs. Shown are average daily temperatures of animals vaccinated with NM (dashed and dotted line), S (dashed line), or adjuvant alone (solid line) and challenged with high doses of NM (◆) or S (□). Temperatures of  $\geq 39.5^{\circ}\text{C}$  were considered fever.

and infection was lethal in three of three NM- and one of three S-challenged animals. Guinea pigs vaccinated with either formalin-killed NM or S were completely protected against fever development and death when challenged with either NM or S (Fig. 5).

## DISCUSSION

The potential for genomic-group-specific pathogenicity of *C. burnetii* was evaluated using immunocompetent mice and guinea pigs and immunodeficient mice. The hypotheses that isolates belonging to the same genomic group would cause similar disease and that there would be distinctions in disease manifestations between isolate groups were supported by the findings presented here.

A detailed analysis of the Priscilla isolate dose-effect in SCID mice revealed differences in virulence of *C. burnetii* isolates. Disease development after Priscilla infection was progressive but slower than the development of the disease caused by NM previously reported in SCID mice (1); the survival time of SCID mice infected with Priscilla was longer with the same  $\text{LD}_{50}$ . This result supports the previous study by Moos and Hackstadt that evaluated the lesser ability of the Priscilla isolate to cause fever in i.p.-challenged guinea pigs (36). Interestingly, the mice infected with Priscilla did not exhibit cachexia until the terminal stages of infection, when they had extremely severe hepatosplenomegaly. Although the disease caused by Priscilla was milder than that associated with NM, all mice that developed clinical illness died. This result confirms the high infectivity and lethal potential of *C. burnetii*, which is not restricted to isolates that cause acute disease, and suggests that

the SCID mouse model can be useful for evaluation of *C. burnetii* virulence.

The virulence of *C. burnetii* isolates tested in SCID mice was determined to be genomic group specific. Acute-Q fever-associated group I isolates caused the most rapidly progressing disease and the most severe pathological changes. Groups IV and V, isolates associated with chronic Q fever, caused a slower progression of disease. Overall, pathological changes in mice infected with group IV and V isolates were milder than those of group I-infected mice. The number of bacteria in the spleen at 28 days p.i. was greater in mice with severe disease from infection with group I isolates; however, the bacterial loads at the time of death were similar in all infected mice. This suggests that the rate of proliferation of *C. burnetii* in vivo may be virulence related. An in vitro comparison of infection in L929 cells using NM, Priscilla, and S isolates showed that all of the isolates could persistently infect, but Priscilla required a greater period of time to establish an infection (42), and it has been shown that inclusion-forming units produced by NM and Priscilla isolates were similar in Vero cells (36). However, because of developmental differences in clinical signs and pathological changes, the replication rate does not seem to be the only virulence factor involved, since clinical signs would then be similar with differences only in disease progression. At both time points, 28 days p.i. and the time of death due to infection, heart and lung lesions caused by group IV, V, and VI isolates were milder than those produced by infection with group I isolates. This observation seems to conflict with the hypothesis that isolates from chronic disease cause chronic Q fever, including heart disease. However, our observation is consistent with the report that isolates from heart lesions of



chronic-Q fever patients have genetic characteristics similar to those of isolates from acute disease (46). The hypothesis that isolates from acute disease do not cause endocarditis has been supported by two other research groups (17, 24). The correlation between virulence and phylogeny has been controversial because of a lack of comprehensive studies. One study detected genes specific to isolates from acute disease in isolates from chronic Q fever patients and concluded that the isolates were not disease specific (46). The isolates used in the study were isolated by cell culture, and although the cell culture system is highly effective for isolation, isolates from acute disease are known to infect cultured cells more efficiently than isolates from chronic disease, so there remains a potential that the study collected only cell culture-adapted isolates. Several *in vivo* studies have reported isolate-specific virulence using guinea pig and mouse models (17, 24, 36); however, the number of isolates used in these studies was limited, making it difficult to conclude that there was genomic-group-specific virulence. The present study using eight isolates from four phylogenetic groups strongly supports the variation in virulence among *C. burnetii* isolate groups.

In the absence of functional T and B cells, cytokine profiles showed no group-specific differences. In immunocompetent mice, group I isolates caused a stronger immune response with high levels of multiple cytokines over a longer time than other groups. Interestingly, Dugway (group VI) induced the least change in CB-17 mice. The inflammatory-cytokine changes in immunocompetent mice in this study were similar to those in humans with acute Q fever (10): TNF- $\alpha$  and IL-6 were upregulated, but IL-1 $\beta$  was not. IFN- $\gamma$  increased in CB-17 mice infected with group I isolates, and it is associated with the control of bacterial growth, stimulates phagosome-lysosome fusion, and may enable monocytes/macrophages to kill *C. burnetii* (13, 14). A difference in vacuole formation between isolates has also been shown, with NM and S developing within single large vacuoles while Priscilla occupied several smaller vacuoles per cell (18). This *in vitro* study suggested a difference in isolate ecology within host cells, which may be correlated with their virulence *in vivo*.

The ability to cause fever and respiratory illness was isolate and dose dependent in the guinea pig aerosol challenge model, with isolates from groups I and V causing disease consistent with human acute Q fever. Isolates within the same genomic group produced similar clinical illnesses, strongly supporting the mouse experiments demonstrating that genomic differences in the bacterial isolates do play a role in virulence. It was shown here that isolates associated with chronic disease, G and S, have the ability to cause acute disease in the guinea pig model. Our study confirmed and expanded the observations of Kazar et al. that the virulence of NM and S isolates was greater than that of Priscilla.

Lesny et al. compared the cross-immunity of whole-cell and soluble Q fever vaccines made from phase I NM, S, Priscilla, and Luga isolates. They found that vaccines from NM and Priscilla afforded a higher degree of protection than S and Luga vaccines and that whole-cell vaccines were more effective than soluble vaccines (28). In the guinea pig challenge study presented here, killed whole-cell vaccines made from isolates differing in LPS banding pattern (16), plasmid type (44), and genomic group (20), specifically isolates from groups I and V,

conferred heterologous protection against virulent high-dose challenge in accordance with previous studies (28). This suggests that although the manifestations of disease and genomic contents differ among various isolate groups, the antigenic properties of whole-cell vaccines are shared enough that cross-protection is possible. Such information is valuable for the design of new vaccines and could be of the utmost importance in offering reliable protection in the event of an outbreak.

The differences in perceived infectious doses noted when ODs, particle counts, and genome copy enumerations were compared underline the importance of using multiple quantitation methods to compare studies with earlier observations. Some of the differences in disease manifestations seen in guinea pigs in this study could be due to slight differences in the infectious doses delivered. For instance, Priscilla and P both induced hepatic changes, although guinea pigs infected with P appeared to develop more severe lesions than those infected with Priscilla, which had a lower infectious dose by OD and qPCR. The difference in infectious dose as determined by the genome copy number could account for this variation. However, G and S both caused fever, and although guinea pigs infected with G did not attain the same degree of febrile response as S-infected animals, quantitation by particle count and real-time PCR showed infectious doses of S to be over a log unit lower than those of G. It could be argued that Priscilla-infected guinea pigs did not develop fever because fewer bacteria were present in the aerosol challenge; however, the group IV isolates did not induce fever at any of the challenge doses while group I isolates induced fever even at the lowest dose. We believe that, despite the variation in the infectious dose depending on the enumeration technique, the significant differences noted among genotypic groups are valid.

Phase variation is the only well-characterized phenotypic difference that is related to virulence in *C. burnetii* (50). Although LPS may be a major virulence determinant, and isolate LPS banding patterns have been correlated with acute or chronic disease (16), other components alone or in association with LPS may be responsible for differences in mortality in SCID mice and fever development in aerosol-challenged guinea pigs. It has been hypothesized that differences in the lipid A component are responsible for the variations in virulence, but lipid structural information indicates they are similar. The combination of a variety of factors expressed by phase I bacteria likely governs the ability of *C. burnetii* to infect cells and to maintain continuous growth within the phagolysosome. Indeed, the combination of pathotype variation of disease in infected guinea pigs and cross-protection of different isolates suggests conserved predominant antigenic components with virulence determinant specificity.

A recent report compared all open reading frames of NM phase I to those of African, Ohio, P, G, S, and Dugway, among others (4), and a majority of the open reading frames deleted from NM in the other isolates were either hypothetical or nonfunctional; however, a few were associated with assorted cellular functions. Beare et al. compared the complete genome sequences of NM, K, G, and Dugway and found distinct collections of pseudogenes and unique gene contents that may contribute to pathotype-specific virulence, including type II and type IV secreted effector molecules (5). Integrating our *in vivo* data with these molecular details, as well as with other in



vitro studies, may reveal the critical virulence determinants of *C. burnetii* and ultimately identify targets for vaccine and therapeutic intervention.

Isolates of phase I *C. burnetii* have the potential to cause a range of clinical signs, including fever, pneumonia, hepatitis, and splenomegaly. Isolates from one human chronic-disease group induced mild to moderate acute disease in the physiologically relevant guinea pig aerosol challenge model, while a separate isolate group representing several chronic-disease isolates caused no acute disease. All isolates examined were capable of producing disease in the immunocompromised SCID mouse model, and genogroup-consistent trends were noted in cytokine production in response to infection in the immunocompetent-mouse model. In these studies, isolates within the same genomic group caused similar pathological responses, with a distinction in strain virulence between established genogroups, sustaining the theory that genetic differences in the bacterial isolates affect their virulence.

#### ACKNOWLEDGMENTS

This work was supported by funding from NIH NIAID grants KO8 AI055664, U54 AI057156, and RO1 AI057768 and Science Research Grant number 13460142 from the Ministry of Education, Science, Sports and Culture of Japan.

We are grateful to Laura R. Hendrix for critical review of the manuscript.

#### REFERENCES

- Andoh, M., T. Naganawa, A. Hotta, T. Yamaguchi, H. Fukushi, T. Masegi, and K. Hirai. 2003. SCID mouse model for lethal Q fever. *Infect. Immun.* 71:4717-4723.
- Arricau-Bouvery, N., Y. Hauck, A. Bejaoui, D. Frangoulidis, C. C. Bodier, A. Souriau, H. Meyer, H. Neubauer, A. Rodolakis, and G. Vergnaud. 2006. Molecular characterization of *Coxiella burnetii* isolates by infrequent restriction site-PCR and MLVA typing. *BMC Microbiol.* 6:38.
- Baumgartner, W., H. Dettlinger, N. Schmeer, and E. Hoffmeister. 1988. Evaluation of different fixatives and treatments for immunohistochemical demonstration of *Coxiella burnetii* in paraffin-embedded tissues. *J. Clin. Microbiol.* 26:2044-2047.
- Beare, P. A., J. E. Samuel, D. Howe, K. Virtaneva, S. F. Porcella, and R. A. Heinzen. 2006. Genetic diversity of the Q fever agent, *Coxiella burnetii*, assessed by microarray-based whole-genome comparisons. *J. Bacteriol.* 188:2309-2324.
- Beare, P. A., N. Unsworth, M. Andoh, D. E. Voth, A. Omsland, S. D. Gilk, K. P. Williams, B. W. Sobral, J. J. Kupko III, S. F. Porcella, J. E. Samuel, and R. A. Heinzen. 2008. Comparative genomics reveal extensive transposon-mediated genomic plasticity and diversity among potential effector proteins within the genus *Coxiella*. *Infect. Immun.* 77:642-656.
- Benenson, A. S., and W. D. Tigertt. 1956. Studies on Q fever in man. *Trans. Assoc. Am. Physicians* 69:98-104.
- Benoit, M., E. Ghigo, C. Capo, D. Raoult, and J. L. Mege. 2008. The uptake of apoptotic cells drives *Coxiella burnetii* replication and macrophage polarization: a model for Q fever endocarditis. *PLoS Pathog.* 4:e1000066.
- Brennan, R. E., and J. E. Samuel. 2003. Evaluation of *Coxiella burnetii* antibiotic susceptibilities by real-time PCR assay. *J. Clin. Microbiol.* 41:1869-1874.
- Brouqui, P. 1993. Chronic Q fever. *Arch. Intern. Med.* 153:642-648.
- Capo, C., N. Amiryan, E. Ghigo, D. Raoult, and J. Mege. 1999. Circulating cytokine balance and activation markers of leucocytes in Q fever. *Clin. Exp. Immunol.* 115:120-123.
- Capo, C., Y. Zaffran, F. Zupan, P. Houpijian, D. Raoult, and J. L. Mege. 1996. Production of interleukin-10 and transforming growth factor  $\beta$  by peripheral blood mononuclear cells in Q fever endocarditis. *Infect. Immun.* 64:4143-4150.
- Ghigo, E., C. Capo, D. Raoult, and J. L. Mege. 2001. Interleukin-10 stimulates *Coxiella burnetii* replication in human monocytes through tumor necrosis factor down-modulation: role in microbicidal defect of Q fever. *Infect. Immun.* 69:2345-2352.
- Ghigo, E., C. Capo, C. H. Tung, D. Raoult, J. P. Gorvel, and J. L. Mege. 2002. *Coxiella burnetii* survival in THP-1 monocytes involves the impairment of phagosome maturation: IFN- $\gamma$  mediates its restoration and bacterial killing. *J. Immunol.* 169:4488-4495.
- Ghigo, E., A. Honstetter, C. Capo, J. P. Gorvel, D. Raoult, and J. L. Mege. 2004. Link between impaired maturation of phagosomes and defective *Coxiella burnetii* killing in patients with chronic Q fever. *J. Infect. Dis.* 190:1767-1772.
- Glazunova, O., V. Roux, O. Freylikman, Z. Sekeyova, G. Fournous, J. Tyczka, N. Tokarevich, E. Kovacava, T. J. Marrie, and D. Raoult. 2005. *Coxiella burnetii* genotyping. *Emerg. Infect. Dis.* 11:1211-1217.
- Hackstadt, T. 1986. Antigenic variation in the phase I lipopolysaccharide of *Coxiella burnetii* isolates. *Infect. Immun.* 52:337-340.
- Hackstadt, T. 1990. The role of lipopolysaccharides in the virulence of *Coxiella burnetii*. *Ann. N. Y. Acad. Sci.* 590:27-32.
- Hechemy, K. E., M. McKee, M. Marko, W. A. Samsonoff, M. Roman, and O. Baca. 1993. Three-dimensional reconstruction of *Coxiella burnetii*-infected L929 cells by high-voltage electron microscopy. *Infect. Immun.* 61:4485-4488.
- Hendrix, L., and L. P. Mallavia. 1984. Active transport of proline by *Coxiella burnetii*. *J. Gen. Microbiol.* 130:2857-2863.
- Hendrix, L. R., J. E. Samuel, and L. P. Mallavia. 1991. Differentiation of *Coxiella burnetii* isolates by analysis of restriction-endonuclease-digested DNA separated by SDS-PAGE. *J. Gen. Microbiol.* 137:269-276.
- Honstetter, A., G. Imbert, E. Ghigo, F. Gouriet, C. Capo, D. Raoult, and J. L. Mege. 2003. Dysregulation of cytokines in acute Q fever: role of interleukin-10 and tumor necrosis factor in chronic evolution of Q fever. *J. Infect. Dis.* 187:956-962.
- Huebner, R. J., W. L. Jellison, and M. D. Beck. 1949. Q fever studies in southern California. III. Effects of pasteurization on survival of *Coxiella burnetii* in naturally infected milk. *Public Health Rep.* 64:499-511.
- Jager, C., H. Willems, D. Thiele, and G. Baljer. 1998. Molecular characterization of *Coxiella burnetii* isolates. *Epidemiol. Infect.* 120:157-164.
- Kazar, J., M. Lesny, P. Propper, D. Valkova, and R. Brezina. 1993. Comparison of virulence for guinea pigs and mice of different *Coxiella burnetii* phase I strains. *Acta Virol.* 37:437-448.
- Koster, F. T., J. C. Williams, and J. S. Goodwin. 1985. Cellular immunity in Q fever: modulation of responsiveness by a suppressor T cell-monocyte circuit. *J. Immunol.* 135:1067-1072.
- La Scola, B., H. Lepidi, and D. Raoult. 1997. Pathologic changes during acute Q fever: influence of the route of infection and inoculum size in infected guinea pigs. *Infect. Immun.* 65:2443-2447.
- Lennette, E. H., W. H. Clark, M. M. Abinanti, O. Brunetti, and J. M. Covert. 1952. Q fever studies. XIII. The effect of pasteurization on *Coxiella burnetii* in naturally infected milk. *Am. J. Hyg.* 55:246-253.
- Lesny, M., J. Kazar, P. Propper, and M. Lukacova. 1991. Virulence and cross-immunity study on guinea pigs infected with different phase I *Coxiella burnetii* strains, p. 666-673. In J. Kazar and D. Raoult (ed.), *Rickettsiae and rickettsial diseases*. Publishing House of the Slovak Academy of Sciences, Bratislava, Slovakia.
- Madariaga, M. G., J. Pulvirenti, M. Sekosan, C. D. Paddock, and S. R. Zaki. 2004. Q fever endocarditis in HIV-infected patients. *Emerg. Infect. Dis.* 10:501-504.
- Marrie, T. J. 1990. Acute Q fever, p. 125-160. In T. J. Marrie (ed.), *Q fever*, vol. 1. The disease. CRC Press, Boca Raton, FL.
- Marrie, T. J. 1990. Q fever hepatitis, p. 171-178. In T. J. Marrie (ed.), *Q fever*, vol. 1. The disease. CRC Press, Boca Raton, FL.
- Marrie, T. J. 2004. Q fever pneumonia. *Curr. Opin. Infect. Dis.* 17:137-142.
- Marrie, T. J., A. Stein, D. Janigan, and D. Raoult. 1996. Route of infection determines the clinical manifestations of acute Q fever. *J. Infect. Dis.* 173:484-487.
- Maurin, M., and D. Raoult. 1999. Q fever. *Clin. Microbiol. Rev.* 12:518-553.
- McMurray, D. N. 1994. Guinea pig model of tuberculosis, p. 135-147. In B. R. Bloom (ed.), *Tuberculosis: pathogenesis, protection, and control*. American Society for Microbiology, Washington, DC.
- Moos, A., and T. Hackstadt. 1987. Comparative virulence of intra- and interstrain lipopolysaccharide variants of *Coxiella burnetii* in the guinea pig model. *Infect. Immun.* 55:1144-1150.
- Ormsbee, R. A. 1965. Q fever rickettsia, p. 1144-1160. In F. L. Horsfall and I. Tamm (ed.), *Viral and rickettsial diseases of man*. J. B. Lippincott, Philadelphia, PA.
- Reference deleted.
- Penttila, I. A., R. J. Harris, P. Storm, D. Haynes, D. A. Worswick, and B. P. Marmion. 1998. Cytokine dysregulation in the post-Q-fever fatigue syndrome. *QJM* 91:549-560.
- Raoult, D., and T. Marrie. 1995. Q Fever. *Clin. Infect. Dis.* 20:489-496.
- Raoult, D., A. Raza, and T. J. Marrie. 1990. Q fever endocarditis and other forms of chronic Q fever, p. 179-120. In T. J. Marrie (ed.), *Q fever*, vol. 1. The disease. CRC Press, Boca Raton, FL.
- Roman, M. J., H. A. Crissman, W. A. Samsonoff, K. E. Hechemy, and O. G. Baca. 1991. Analysis of *Coxiella burnetii* isolates in cell culture and the expression of parasite-specific antigens on the host membrane surface. *Acta Virol.* 35:503-510.
- Russell-Lodrigue, K. E., G. Q. Zhang, D. N. McMurray, and J. E. Samuel. 2006. Clinical and pathologic changes in a guinea pig aerosol challenge model of acute Q fever. *Infect. Immun.* 74:6085-6091.
- Samuel, J. E., M. E. Frazier, and L. P. Mallavia. 1985. Correlation of

- plasmid type and disease caused by *Coxiella burnetii*. *Infect. Immun.* 49:775-779.
45. Scott, G. H., J. C. Williams, and E. H. Stephenson. 1987. Animal models in Q fever: pathological responses of inbred mice to phase I *Coxiella burnetii*. *J. Gen. Microbiol.* 133:691-700.
  46. Stein, A., and D. Raoult. 1993. Lack of pathotype specific gene in human *Coxiella burnetii* isolates. *Microb. Pathog.* 15:177-185.
  47. Stoenner, H. G., R. Holdenried, D. Lackman, and J. S. Orsborn. 1959. The occurrence of *Coxiella burnetii*, *Brucella*, and other pathogens among fauna of the Great Salt Lake Desert in Utah. *Am. J. Trop. Med. Hyg.* 8:590-595.
  48. Stoenner, H. G., and D. B. Lackman. 1960. The biologic properties of *Coxiella burnetii* isolated from rodents collected in Utah. *Am. J. Hyg.* 71:45-51.
  49. Svraka, S., R. Toman, L. Skultety, K. Slaba, and W. L. Homan. 2006. Establishment of a genotyping scheme for *Coxiella burnetii*. *FEMS Microbiol. Lett.* 254:268-274.
  50. Thiele, D., and H. Willems. 1994. Is plasmid based differentiation of *Coxiella burnetii* in 'acute' and 'chronic' isolates still valid? *Eur. J. Epidemiol.* 10:427-434.
  51. Tissot Dupont, H., D. Raoult, P. Brouqui, F. Janbon, D. Peyramond, P. J. Weiller, C. Chicheportiche, M. Nezri, and R. Poirier. 1992. Epidemiologic features and clinical presentation of acute Q fever in hospitalized patients: 323 French cases. *Am. J. Med.* 93:427-434.
  52. Wiegshaas, E. H., D. N. McMurray, A. A. Grover, G. E. Harding, and D. W. Smith. 1970. Host-parasite relationships in experimental airborne tuberculosis. 3. Relevance of microbial enumeration to acquired resistance in guinea pigs. *Am. Rev. Respir. Dis.* 102:422-429.
  53. Williams, J. C., M. G. Peacock, and T. F. McCaul. 1981. Immunological and biological characterization of *Coxiella burnetii*, phase I and phase II, separated from host components. *Infect. Immun.* 32:840-851.
  54. Zhang, G. Q., and J. E. Samuel. 2003. Identification and cloning potentially protective antigens of *Coxiella burnetii* using sera from mice experimentally infected with Nine Mile phase I. *Ann. N. Y. Acad. Sci.* 990:510-520.

---

Editor: R. P. Morrison

# Evolutional and Geographical Relationships of *Bartonella grahamii* Isolates from Wild Rodents by Multi-locus Sequencing Analysis

Kai Inoue · Hidenori Kabeya · Michael Y. Kosoy ·  
Ying Bai · George Smirnov · Dorothy McColl ·  
Harvey Artsob · Soichi Maruyama

Received: 22 June 2008 / Accepted: 19 January 2009 / Published online: 14 February 2009  
© Springer Science + Business Media, LLC 2009

**Abstract** To clarify the relationship between *Bartonella grahamii* strains and both the rodent host species and the geographic location of the rodent habitat, we have investigated 31 *B. grahamii* strains from ten rodent host species from Asia (Japan and China), North America (Canada and the USA), and Europe (Russia and the UK). On the basis of multi-locus sequencing analysis of 16S rRNA, *ftsZ*, *gltA*, *groEL*, *ribC*, and *rpoB*, the strains were classified into two large groups, an Asian group and an American/European group. In addition, the strains examined were clearly clustered according to the geographic locations where the rodents had been captured. In the phylogenetic analysis based on *gltA*, the Japanese strains were divided into two subgroups: one close to strains from China, and the other

related to strains from Far Eastern Russia. Thus, these observations suggest that the *B. grahamii* strains distributed in Japanese rodents originated from two different geographic regions. In the American/European group, *B. grahamii* from the North American continent showed an ancestral lineage and strict host specificity; by contrast, European strains showed low host specificity. The phylogenetic analysis and host specificity of *B. grahamii* raise the possibility that *B. grahamii* strains originating in the North American continent were distributed to European countries by adapting to various rodent hosts.

## Introduction

The genus *Bartonella* was formerly classified as the genera *Bartonella*, *Grahamella*, and *Rochalimaea*. These microorganisms are Gram-negative, fastidious, and hemotropic bacteria that are mainly transmitted by blood-sucking arthropod vectors [7]. The genus *Bartonella* now consists of 20 species and three subspecies; 11 species or subspecies of them, including *Bartonella birtlesii* [2], *Bartonella dohiae* [4], *Bartonella elizabethae* [8], *Bartonella grahamii* [4], *Bartonella phoceensis* [12], *Bartonella rattimassiliensis* [12], *Bartonella taylorii* [4], *Bartonella tribocorum* [14], *Bartonella vinsonii* subsp. *arupensis* [35], *Bartonella vinsonii* subsp. *vinsonii* [5, 22], and *Bartonella washoensis* [23] have been isolated from diverse wild rodent species. Some *Bartonella* species have been shown to have strict host specificity in epidemiological studies [6, 17, 24] and by experimental infection using cotton rats (*Sigmodon hispidus*), white-footed mice (*Peromyscus leucopus*), and other rodent species together with specific *Bartonella* species [25].

K. Inoue · H. Kabeya · S. Maruyama (✉)  
Laboratory of Veterinary Public Health,  
Department of Veterinary Medicine,  
College of Bioresource Sciences, Nihon University,  
1866 Kameino, Fujisawa,  
Kanagawa 252-8510, Japan  
e-mail: maruyama.soichi@nihon-u.ac.jp

M. Y. Kosoy · Y. Bai  
Division of Vector-Borne Infectious Diseases,  
National Center for Infectious Diseases,  
Centers for Disease Control and Prevention,  
Fort Collins, CO, USA

G. Smirnov  
Gamaleya Research Institute of Epidemiology and Microbiology,  
Russian Academy of Medical Sciences,  
Moscow, Russia

D. McColl · H. Artsob  
National Microbiology Laboratory,  
Public Health Agency of Canada,  
Winnipeg, MB, Canada

*B. grahamii* was first isolated from *Myodes glareolus* (formerly *Clethrionomys glareolus*) in the UK in 1995 [3]. Subsequently, it was shown that this bacterial species is widely distributed all over the world, including Asia [16, 29, 36], Europe [9, 15, 33], and North America [10, 17], and *B. grahamii* has been isolated from various rodent species—namely, the genera *Myodes*, *Apodemus*, *Microtus*, *Mus*, and *Dryomys*. In a clinical study, the DNA of *B. grahamii* was detected in the ocular fluid of a patient with neuroretinitis [20], suggesting that the organism is potentially pathogenic to human. Despite its widespread distribution, little is known about how *B. grahamii* strains from different countries in Asia, Europe, and North America are related.

In this study, we have investigated the relationship between *B. grahamii* strains and both the host rodent species and the geographic location of the host habitat by analyzing the DNA sequences of strains from rodents in Japan, China, Canada, the USA, Russia, and the UK. For this purpose, we performed multi-locus sequencing analysis (MLSA), targeting the genes encoding 16S rRNA [13], cell-division protein (*ftsZ*) [38], citrate synthase (*gltA*) [30], 60 kDa heat-shock protein (*groEL*) [37], riboflavin synthase alpha chain (*ribC*) [1, 18], and RNA polymerase beta subunit (*rpoB*) [31].

## Materials and Methods

### Bacterial Strains and Culture Conditions

A total of 31 *B. grahamii* strains, including the type strain, were used in this study (Table 1). These strains were isolated from ten rodent species: a large Japanese field mouse (*Apodemus speciosus*,  $n=10$ ), a small Japanese field mouse (*Apodemus argenteus*,  $n=5$ ), a Chevriér's field mouse (*Apodemus chevriéri*,  $n=1$ ), a south China field mouse (*Apodemus draco*,  $n=1$ ), a large-eared field mouse (*Apodemus latronum*,  $n=2$ ), a Gapper's red-backed vole (*Myodes gapperi*,  $n=6$ ), a prairie vole (*Microtus ochrogaster*,  $n=3$ ), an Ural field mouse (*Apodemus uralensis*,  $n=1$ ), a yellow-necked mouse (*Apodemus flavicollis*,  $n=1$ ), and a bank vole (*Myodes glareolus*,  $n=1$ ). The strains were derived from six countries: Japan ( $n=15$ ), China ( $n=4$ ), Canada ( $n=6$ ), the USA ( $n=3$ ), Russia ( $n=2$ ), and the UK ( $n=1$ ). All of these strains were genetically identified as *B. grahamii* by sequencing a fragment of *gltA* before the present study. In addition, the sequence information of *gltA* of *B. grahamii* obtained from a house mouse (*Mus musculus*) captured in California, USA (GenBank accession number AF086637) and those of *B. grahamii* from the spleen and liver of rodents (*Apodemus peninsulae* and *Apodemus agrarius*) in Far Eastern Russia (AY584854–AY584857) were also included in this study [10, 29].

All bacterial strains were cultured on heart infusion agar plates (DIFCO, MI, USA) containing 5% defibrinated rabbit blood. The plates were cultured at 35°C in a 5% CO<sub>2</sub> atmosphere for 2 weeks, and harvested bacteria were used for DNA extraction.

### DNA Extraction and Polymerase Chain Reaction (PCR) of 16S rRNA, *ftsZ*, *gltA*, *groEL*, *ribC*, and *rpoB*

Genomic DNA was extracted from each strain by using an Instagene Matrix (Bio Rad, CA, USA). The extracted DNA was used for PCR amplification of 16S rRNA, *ftsZ*, *gltA*, *groEL*, *ribC*, and *rpoB* [27]. The PCR amplification of each gene was performed in a volume of 20 µl containing 20 ng of extracted DNA, 200 µM each of dATP, dGTP, dCTP, and dTTP, 1.5 mM MgCl<sub>2</sub>, 0.5 U of *Taq* DNA polymerase (Promega, WI, USA), and 1 pmol of each primer. The primers and PCR conditions for 16S rRNA [13], *ftsZ* [38], *gltA* [30], *groEL* [37], and *rpoB* [31] were the same as described in previous reports. The primer pair for *ribC* was originally designed in this study as ribC5'-NU (5'-ARA-TGGAGGCGTAAGAYAYT-3') and ribC3'-NU (5'-AARC-GYGCTTCAACAATCAA-3'), and the PCR conditions for amplification of *ribC* were as follows: denaturation at 94°C for 4 min, 35 cycles of denaturation at 94°C for 30 s, annealing at 49°C for 30 s, extension at 72°C for 60 s, and a final extension at 72°C for 7 min.

### Direct DNA Sequencing Analysis

The PCR products were purified by using a SpinColumn PCR Product Purification Kit (Bio Basic, Ontario, Canada). Direct DNA sequencing of the purified PCR products was carried out by dye terminator chemistry with specific primers for 16S rRNA [13], *ftsZ* [38], *gltA* [30], *groEL* [37], and *rpoB* [31] and for *ribC* (see above) using a Genetic Analyzer model 3130 (Applied Biosystem, CA, USA).


### Phylogenetic Analysis and Construction of Phylogenetic Trees

The sequence data for 16S rRNA (1,348 bp), *ftsZ* (788 bp), *gltA* (312 bp), *groEL* (1,185 bp), *ribC* (618 bp), and *rpoB* (825 bp) from the 31 *B. grahamii* strains were aligned with those of the type strains of *Bartonella* species by using CLUSTAL X version 1.83 [34]. A phylogenetic tree covering 5,076 bp of concatenated data from the six loci was drawn by using the neighbor-joining (NJ) method [32] in the MEGA 3.1 software program [26] with the Jukes–Cantor parameters method [19], which is based on the assumption that all nucleotide substitutions are equally likely. Bootstrap analysis was carried out on 1,000 replications [11].

Table 1 Geographical origin, host rodent species, and GenBank accession numbers of the six loci used for MLSA of 31 *B. grahamii* strains

No.	Country/location	Host rodent species	Strain	GenBank accession number					
				16S rRNA	<i>ftsZ</i>	<i>gltA</i>	<i>groEL</i>	<i>ribC</i>	<i>rpoB</i>
1	Japan/Hokkaido	<i>Apodemus speciosus</i>	Hokkaido 4-1	AB426629	AB426638	AB426652	AB426657	AB426678	AB426691
2	Japan/Hokkaido	<i>A. argentus</i>	Hokkaido 48-1	AB426630	AB426639	Identical to No. 1	Identical to No. 1	Identical to No. 1	AB426692
3	Japan/Aomori	<i>A. speciosus</i>	Aomori 23-1	Identical to No. 1	AB426640	Identical to No. 1	AB426658	Identical to No. 1	AB259947
4	Japan/Aomori	<i>A. argentus</i>	Aomori 40-1	Identical to No. 1	Identical to No. 3	Identical to No. 1	Identical to No. 1	Identical to No. 1	Identical to No. 1
5	Japan/Kanagawa	<i>A. speciosus</i>	Fujisawa 5-1	Identical to No. 1	Identical to No. 1	Identical to No. 1	AB426659	Identical to No. 1	Identical to No. 1
6	Japan/Kanagawa	<i>A. argentus</i>	Fujisawa 1-1	Identical to No. 1	Identical to No. 3	Identical to No. 1	Identical to No. 1	Identical to No. 1	Identical to No. 1
7	Japan/Shizuoka	<i>A. speciosus</i>	Fuji 4-1	Identical to No. 1	AB426641	Identical to No. 1	AB426660	Identical to No. 1	Identical to No. 1
8	Japan/Shizuoka	<i>A. argentus</i>	Fuji 6-1	Identical to No. 2	Identical to No. 2	Identical to No. 2	AB426661	Identical to No. 1	AB242285
9	Japan/Nagano	<i>A. speciosus</i>	Nagano 3-1	Identical to No. 1	Identical to No. 2	Identical to No. 1	AB426662	Identical to No. 1	AB290260
10	Japan/Nagano	<i>A. argentus</i>	Nagano 32-1	Identical to No. 1	Identical to No. 3	AB290289	Identical to No. 1	Identical to No. 1	Identical to No. 1
11	Japan/Ishikawa	<i>A. speciosus</i>	Ishikawa 4-1	Identical to No. 2	Identical to No. 3	Identical to No. 1	Identical to No. 1	Identical to No. 1	Identical to No. 1
12	Japan/Tokushima	<i>A. speciosus</i>	Tokushima 4-1	AB426631	AB426642	AB290291	AB426663	AB426679	AB426693
13	Japan/Ehime	<i>A. speciosus</i>	Ehime 1-1	Identical to No. 12	Identical to No. 12	Identical to No. 12	AB426664	Identical to No. 12	Identical to No. 12
14	Japan/Kagoshima	<i>A. speciosus</i>	Nakanoshima 7-1	Identical to No. 2	Identical to No. 1	Identical to No. 1	Identical to No. 1	AB426680	Identical to No. 1
15	Japan/Kagoshima	<i>A. speciosus</i>	Nakanoshima 10-1	Identical to No. 12	Identical to No. 12	Identical to No. 13	AB426665	Identical to No. 12	Identical to No. 12
16	China/Yunnan	<i>A. chevrieri</i>	Ac1692yn	AB426632	AB426643	AF391271	AB426666	AB426681	AB426694
17	China/Yunnan	<i>A. draco</i>	Ad1734yn	AB426633	AB426644	AF391277	AB426667	AB426682	AB426695
18	China/Yunnan	<i>A. latronum</i>	AL1707yn	Identical to No. 18	AB426645	AF391275	AB426668	AB426683	AB426696
19	China/Yunnan	<i>A. latronum</i>	AL1714yn	Identical to No. 18	Identical to No. 16	AF391280	AB426669	AB426684	AB426697
20	Russia/Moscow	<i>A. uralensis</i>	PTZB 29/18	AB426634	AB426646	Identical to No. 1	AB426675	AB426689	Identical to No. 31
21	Russia/Moscow	<i>A. flavicollis</i>	PTZA 30/3	Identical to No. 21	AB426647	Identical to No. 31	AB426676	Identical to No. 20	Identical to No. 31
22	Canada/Alberta	<i>Myodes gapperi</i>	Cg4224alb	Identical to No. 1	AB426648	AB426654	AB426670	AB426685	AB426698
23	Canada/Alberta	<i>My. gapperi</i>	Cg4226alb	Identical to No. 1	Identical to No. 22	Identical to No. 22	AB426671	AB426686	AB426699
24	Canada/Alberta	<i>My. gapperi</i>	Cg4227alb	Identical to No. 1	Identical to No. 22	Identical to No. 22	AB426672	Identical to No. 23	Identical to No. 23
25	Canada/Alberta	<i>My. gapperi</i>	Cg4228alb	Identical to No. 1	Identical to No. 22	Identical to No. 22	AB426673	AB426687	AB426700
26	Canada/Alberta	<i>My. gapperi</i>	Cg4263alb	AB426635	AB426649	Identical to No. 22	AB426674	AB426688	AB426701
27	Canada/Alberta	<i>My. gapperi</i>	Cg4285alb	AB426636	Identical to No. 26	Identical to No. 22	Identical to No. 26	Identical to No. 26	Identical to No. 26
28	USA/South Dakota	<i>Microtus ochrogaster</i>	B12509	Identical to No. 1	AB426650	AB426655	AB426677	AB426690	AB426702
29	USA/South Dakota	<i>Mi. ochrogaster</i>	B12511	AB426637	AB426651	Identical to No. 28	Identical to No. 28	Identical to No. 28	Identical to No. 28
30	USA/South Dakota	<i>Mi. ochrogaster</i>	B12512	Identical to No. 1	Identical to No. 29	Identical to No. 28	Identical to No. 28	Identical to No. 28	Identical to No. 28
31	UK/Shropshire	<i>My. glareolus</i>	V2 <sup>T</sup>	Z31349	AF467753	Z70016	AF014833	AY166583	AF165993

T type strain



**Figure 1** Phylogenetic tree of the 31 *B. grahamii* strains examined here and known *Bartonella* species constructed by the NJ method with Jukes–Cantor parameters based on the concatenated nucleotide sequences (5,076 bp) of 16 S rRNA, *ftsZ*, *gltA*, *groEL*, *ribC*, and *rpoB*. The derived host rodent species and the country of origin of the strains are shown after each slash. Bootstrap values (percentage of 1,000 replications) of >70% are indicated at the node. The sequences

of *Brucella melitensis* strain 16M and *Agrobacterium tumefaciens* strain C58 have been chosen as outgroups in the phylogenetic tree. The abbreviations of the host species are as follows: *Aar*, *Apodemus argenteus*; *Ach*, *Apodemus chevrieri*; *Adr*, *Apodemus draco*; *Afl*, *Apodemus flavicollis*; *Ala*, *Apodemus latronum*; *Asp*, *Apodemus speciosus*; *Aur*, *Apodemus uralensis*; *Mga*, *Myodes gapperi*; *Mgl*, *Myodes glareolus*; and *Moc*, *Microtus ochrogaster*

In addition to the *gltA* sequence from the 31 strains, five *gltA* sequences of strains from a *Mu. musculus* host captured in California, USA (AF086637), and from *A. peninsulae* and *A. agrarius* hosts in Far Eastern Russia (AY584854–AY584857) were also included in the following analysis. The data for the 36 *gltA* sequences were aligned with those of the type strains of *Bartonella* species by the same method used for the concatenated sequences of the six loci, and a phylogenetic tree based on *gltA* was constructed by the NJ method with Kimura's two-parameter distance method [21].


## Results

### Phylogenetic Analysis by using the Concatenated Sequences of the Six Loci

The DNA fragments of all six loci, including 16S rRNA, *ftsZ*, *gltA*, *groEL*, *ribC*, and *rpoB*, of the 31 *B. grahamii* strains

were successfully sequenced and GenBank accession numbers were obtained (Table 1). The strains were classified into 10, 15, 12, 22, 14, and 16 sequence types (STs) for 16S rRNA, *ftsZ*, *gltA*, *groEL*, *ribC*, and *rpoB*, respectively. The sequence similarity of the concatenated sequences (5,076 bp) of the strains according to country was 97.8–100% in Japan, 97.3–99.6% in China, 99.5–100% in Canada, 99.9–100% in the USA, and 99.8% in Russia. The sequence similarity of the strains according to host rodent genera was 95.5–99.9% in *Apodemus* mice, 98.2–99.9% in *Myodes* voles, and 99.9–100% in *Microtus* voles.

The phylogenetic tree based on the concatenated sequences is shown in Fig. 1. The strains branched to two large groups, an Asian group and an America/European group, with a high bootstrap value (>97%). In the Asian group, *B. grahamii* strains derived from Japan were classified into two subgroups, termed Japan 1 and Japan 2. Although the strains in Japan 1, which were derived from geographic locations throughout Japan, formed a separate clade, three strains in



**Figure 2** Phylogenetic tree of the 31 *B. grahamii* strains examined here and known *Bartonella* species constructed by the NJ method with Kimura's two-parameter distances method based on a part of *gltA* (312 bp). The GenBank accession numbers are indicated in parentheses. The phylogenetic tree includes partial sequences of *B. grahamii* from *Apodemus agrarius* and *A. peninsulae* in Far Eastern Russia (AY584854–AY584857) and from *Mus musculus* in the USA (AF086637). The derived host rodent species and country are shown after each slash. Bootstrap values (percentage of 1,000 replications) of

>70% are indicated at the node. The sequences of *Brucella melitensis* strain 16M and *Agrobacterium tumefaciens* strain C58 have been chosen as outgroups. The abbreviations of host species are as follows: *Aag*, *Apodemus agrarius*; *Aar*, *Apodemus argenteus*; *Ach*, *Apodemus chevrieri*; *Adr*, *Apodemus draco*; *Afl*, *Apodemus flavicollis*; *Ala*, *Apodemus latronum*; *Ape*, *Apodemus peninsulae*; *Asp*, *Apodemus speciosus*; *Aur*, *Apodemus uralensis*; *Mga*, *Myodes gapperi*; *Mgl*, *Myodes glareolus*; *Mmu*, *Mus musculus*, and *Moc*, *Microtus ochrogaster*

Japan 2 (i.e., Ehime 1-1, Nakanoshima 10-1, and Tokushima 4-1) that were derived from the southern part of Japan formed a large clade with the Chinese strains. Strains from Canada, the UK, Russia, and the USA formed a large clade as the American/European group. The strains from the USA were more closely related to those from the UK and Russia than to those from Canada.


All of the *B. grahamii* strains examined, except those from *Apodemus* mice, were grouped according to their host rodent genera (Fig. 1). Strains from Japanese and Chinese *Apodemus* mice belonged to the Asian group, whereas those from Russia were present in the American/European group.

#### Phylogenetic Analysis by *gltA*

The 31 strains were classified into 12 STs, and the sequence similarity among all 31 strains ranged from 96.5% to 100% (0–11 bp difference in 312 bp). The sequence similarities among the strains by country were 97.1–100% in Japan, 98.4–100% in China, 97.0–100% in Russia, 100% in Canada, and 99.4–100% in the USA, respectively. The sequence similarity in strains according to host rodent genera was 96.5–100% in *Apodemus* mice, 99.0–100% in *Myodes* voles, and 99.4–100% in *Microtus* voles.

The phylogenetic tree of *gltA* corresponded well with that of the concatenated sequences (Fig. 2). The strains





**Figure 3** Geographic distribution of *B. grahamii* strains and their host rodent species. The areas where the *B. grahamii* strains of the Asian group and the American/European group have been isolated are indicated by open circles (○) and squares (□), respectively. The

formed clades according to the geographic locations where the rodents had been captured, although the Japanese strains formed two clades, namely JP1-gltA and JP2-gltA. Almost all Japanese strains were included in clade JP1-gltA; by contrast, clade JP2-gltA consisted of only three strains (i.e., Ehime 1-1, Nakanoshima 10-1, and Tokushima 4-1) that were isolated from the southern part of Japan. Three of the four sequences of *B. grahamii* (AY584854, AY584855, and AY584856) derived from two *A. agrarius* hosts and an *A. peninsulae* host in Far Eastern Russia were also clustered in clade JP1-gltA from Japan with 98.4–100% similarity. The remaining *B. grahamii* sequence (AY584857) from *A. agrarius* host in Far Eastern Russia formed a clade with the strains from *Microtus* voles in the USA, sharing 99.7% similarity. A sequence (AF086637) of *B. grahamii* derived from *Mus musculus* host captured in California, USA, was related to strains from Canada, the UK, Russia, and the USA with 97.4–98.4% similarity, but it was located outside the strains showing ancestral lineage.

As found for the concatenated sequences, all of the *B. grahamii* strains examined, except those from *Apodemus*

distribution of two different *B. grahamii* groups in Japan (Japan/Far Eastern Russia and Japan/China) is indicated by a closed circle (●) and triangle (▲), respectively

mice, were grouped according to their host rodent genera (Fig. 2). Two strains from *A. uralensis* and *A. flavicollis* hosts in Russia had sequences identical to that of a strain from a *Myodes* vole in the UK. The sequence (AY584857) of *B. grahamii* from *A. agrarius* host in Far Eastern Russia was closely related to those from *Microtus* voles in the USA (99.4–99.7% similarity).

**Discussion**

Previous studies have isolated *B. grahamii* from various rodents, including the genera *Myodes*, *Apodemus*, *Microtus*, *Mus*, and *Dryomys*, and have shown that this microorganism is widely distributed over all of the continents such as Asia [16, 29, 36], Europe [9, 15, 33], and North America [10, 17]. By MLSA, the 31 *B. grahamii* strains analyzed here showed genetic divergence and were classified into 10, 15, 12, 22, 14, and 16 STs for 16S rRNA, *ftsZ*, *gltA*, *groEL*, *ribC*, and *rpoB*, respectively. The diversity observed among *B. grahamii* strains from different parts of the world

provides a better understanding of evolutionary history of the organisms.

From the phylogenetic tree of the concatenated sequences, the strains were classified into two large groups according to geographical region: namely, an Asian group and an American/European group. All of the *B. grahamii* strains, except those from *Apodemus* mice, were also classified according to their host rodent genera in the phylogenetic analysis of both the concatenated sequences and the *gltA* sequences. However, *Apodemus* mice from Japan, China, and Russia were shown to harbor two different types of strain belonging to the Asian and the American/European group, indicating that *B. grahamii* are more accurately classified according to geographical region rather than to the host rodent genera. To confirm this hypothesis, it will be necessary to examine the genetic profiles of greater numbers of *B. grahamii* strains from many areas of the world.

In the phylogenetic analysis of the concatenated sequences, the Asian group consisted of strains from Japan and China, and the Japanese strains were divided into two subgroups, termed Japan 1 and Japan 2. The strains Ehime 1-1, Nakanoshima 10-1, and Tokushima 4-1 of subgroup Japan 2 were derived from the southern part of Japan and were more closely related to Chinese strains than to the strains of subgroup Japan 1. On the other hand, the phylogenetic analysis of *gltA* showed that the sequences of JP1-*gltA* were closely related to three sequences obtained from two *A. agrarius* hosts and an *A. peninsulae* host from Far Eastern Russia. On the basis of these phylogenetic analyses, we hypothesize that the *B. grahamii* strains distributed in wild rodents in Japan originated from two different geographic regions, i.e., China and Far Eastern Russia (Fig. 3). Furthermore, a sequence (AY584857) of *B. grahamii* from Far Eastern Russia was closely related to the sequences of *B. grahamii* from the USA. These findings suggest that Far Eastern Russia is one of the areas where *B. grahamii* strains of the Asian and American/European group might coexist (Fig. 3).

Phylogenetic analysis of the concatenated sequences showed that strains from the North American continent (Canada and the USA) and the European continent (the UK and Russia) were related to each other and formed a large clade, namely, the American/European group. In the phylogenetic analysis of *gltA*, a sequence (AF086637) of *B. grahamii* from *Mu. musculus* host in the USA was located outside the clades comprising strains from Canada, the UK, Russia, and the USA. Therefore, *B. grahamii* from *Mu. musculus* host in the USA is likely to be an ancestral lineage that previously branched away from the other strains of the American/European group. Furthermore, strict host specificity between *B. grahamii* and *My. gapperi* has been observed in Canada even though many rodent species

exist there [17]. By contrast, *B. grahamii* strains in Europe have been isolated from a variety of host rodent species such as *A. uralensis* and *A. flavicollis* in Russia [28] and *A. sylvaticus*, *My. glareolus*, and *Mi. agrestis* in the UK [3]. These findings suggest the possibility that the geographic origin of *B. grahamii* strains of the American/European group is the North American continent rather than the European continent and that the organisms migrated with their rodent hosts and subsequently were distributed to many host rodent species in European countries. Therefore, we hypothesize that *B. grahamii* crossed the Bering Strait with their host rodents from the North American continent to Eurasia during the glacial epoch of the Pleistocene and may have been distributed through their ability to adapt to a wide range of host rodents (Fig. 3).

**Acknowledgements** This work was supported by a Grant for Academic Frontier Project, Surveillance and Control for Zoonoses, from the Ministry of Education, Culture, Sports, Science and Technology and also supported by a Grant-in-Aid from the Ministry of Health, Labour and Welfare, Japan.

## References

1. Bereswill S, Hinkelmann S, Kist M, Sander A (1999) Molecular analysis of riboflavin synthesis genes in *Bartonella henselae* and use of the *ribC* gene for differentiation of *Bartonella* species by PCR. *J Clin Microbiol* 37:3159–3166
2. Bermond D, Heller R, Barrat F, Delacour G, Dehio C, Alliot A, Monteil H, Chomel B, Boulouis HJ, Piemont Y (2000) *Bartonella birtlesii* sp. nov., isolated from small mammals (*Apodemus* spp.). *Int J Syst Evol Microbiol* 50(Pt 6):1973–1979
3. Birtles RJ, Harrison TG, Molyneux DH (1994) *Grahamella* in small woodland mammals in the U.K. isolation, prevalence and host specificity. *Ann Trop Med Parasitol* 88:317–327
4. Birtles RJ, Harrison TG, Saunders NA, Molyneux DH (1995) Proposals to unify the genera *Grahamella* and *Bartonella*, with descriptions of *Bartonella talpae* comb. nov., *Bartonella peromysci* comb. nov., and three new species, *Bartonella grahamii* sp. nov., *Bartonella taylorii* sp. nov., and *Bartonella doshaiae* sp. nov. *Int J Syst Bacteriol* 45:1–8
5. Brenner DJ, O'Connor SP, Winkler HH, Steigerwalt AG (1993) Proposals to unify the genera *Bartonella* and *Rochalimaea*, with descriptions of *Bartonella quintana* comb. nov., *Bartonella vinsonii* comb. nov., *Bartonella henselae* comb. nov., and *Bartonella elizabethae* comb. nov., and to remove the family *Bartonellaceae* from the order *Rickettsiales*. *Int J Syst Bacteriol* 43:777–786
6. Castle KT, Kosoy M, Lerdthusnee K, Phelan L, Bai Y, Gage KL, Leepitakrat W, Monkanna T, Khlaimanee N, Chandranoi K, Jones JW, Coleman RE (2004) Prevalence and diversity of *Bartonella* in rodents of northern Thailand: a comparison with *Bartonella* in rodents from southern China. *Am J Trop Med Hyg* 70:429–433
7. Chomel BB, Boulouis HJ, Maruyama S, Breitschwerdt EB (2006) *Bartonella* spp. in pets and effect on human health. *Emerg Infect Dis* 12:389–394
8. Daly JS, Worthington MG, Brenner DJ, Moss CW, Hollis DG, Weyant RS, Steigerwalt AG, Weaver RE, Daneshvar MI, O'Connor SP (1993) *Rochalimaea elizabethae* sp. nov. isolated from a patient with endocarditis. *J Clin Microbiol* 31:872–881

9. Ehrenborg C, Handley S, Ellis B, Mills J, Holmberg M (2003) *Bartonella grahamii* infecting rodents display high genetic diversity over short geographic distances. *Ann N Y Acad Sci* 990:233–235
10. Ellis BA, Regnery RL, Beati L, Bacellar F, Rood M, Glass GG, Marston E, Ksiazek TG, Jones D, Childs JE (1999) Rats of the genus *Rattus* are reservoir hosts for pathogenic *Bartonella* species: an Old World origin for a New World disease. *J Infect Dis* 180:220–224
11. Felsenstein J (1985) Confidence limits on phylogenies: an approach using the bootstrap. *Evolution* 39:783–791
12. Gundi VA, Davoust B, Khamis A, Boni M, Raoult D, La Scola B (2004) Isolation of *Bartonella rattimassiliensis* sp. nov. and *Bartonella phoceensis* sp. nov. from European *Rattus norvegicus*. *J Clin Microbiol* 42:3816–3818
13. Heller R, Artois M, Xemar V, De Briel D, Gehin H, Jaulhac B, Monteil H, Piemont Y (1997) Prevalence of *Bartonella henselae* and *Bartonella clarridgeiae* in stray cats. *J Clin Microbiol* 35:1327–1331
14. Heller R, Riegel P, Hansmann Y, Delacour G, Bermond D, Dehio C, Lamarque F, Monteil H, Chomel B, Piemont Y (1998) *Bartonella tribocorum* sp. nov., a new *Bartonella* species isolated from the blood of wild rats. *Int J Syst Bacteriol* 48(Pt 4):1333–1339
15. Holmberg M, Mills JN, McGill S, Benjamin G, Ellis BA (2003) *Bartonella* infection in sylvatic small mammals of central Sweden. *Epidemiol Infect* 130:149–157
16. Inoue K, Maruyama S, Kabeya H, Yamada N, Ohashi N, Sato Y, Yukawa M, Masuzawa T, Kawamori F, Kadosaka T, Takada N, Fujita H, Kawabata H (2008) Prevalence and genetic diversity of *Bartonella* species isolated from wild rodents in Japan. *Appl Environ Microbiol* 74:5086–5092
17. Jardine C, Appleyard G, Kosoy MY, McColl D, Chirino-Trejo M, Wobeser G, Leighton FA (2005) Rodent-associated *Bartonella* in Saskatchewan, Canada. *Vector Borne Zoonotic Dis* 5:402–409
18. Johnson G, Ayers M, McClure SC, Richardson SE, Tellier R (2003) Detection and identification of *Bartonella* species pathogenic for humans by PCR amplification targeting the riboflavin synthase gene (*ribC*). *J Clin Microbiol* 41:1069–1072
19. Jukes TH, Cantor CR (1969) Evolution of protein molecules. In: Munro HN (ed) *Mammalian protein metabolism*. Academic, New York, pp 21–132
20. Kerkhoff FT, Bergmans AM, van Der Zee A, Rothova A (1999) Demonstration of *Bartonella grahamii* DNA in ocular fluids of a patient with neuroretinitis. *J Clin Microbiol* 37:4034–4038
21. Kimura M (1980) A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. *J Mol Evol* 16:111–120
22. Kordick DL, Swaminathan B, Greene CE, Wilson KH, Whitney AM, O'Connor S, Hollis DG, Matar GM, Steigerwalt AG, Malcolm GB, Hayes PS, Hadfield TL, Breitschwerdt EB, Brenner DJ (1996) *Bartonella vinsonii* subsp. *berkhoffii* subsp. nov., isolated from dogs; *Bartonella vinsonii* subsp. *vinsonii*; and emended description of *Bartonella vinsonii*. *Int J Syst Bacteriol* 46:704–709
23. Kosoy M, Murray M, Gilmore RD Jr, Bai Y, Gage KL (2003) *Bartonella* strains from ground squirrels are identical to *Bartonella washoensis* isolated from a human patient. *J Clin Microbiol* 41:645–650
24. Kosoy MY, Regnery RL, Tzianabos T, Marston EL, Jones DC, Green D, Maupin GO, Olson JG, Childs JE (1997) Distribution, diversity, and host specificity of *Bartonella* in rodents from the Southeastern United States. *Am J Trop Med Hyg* 57:578–588
25. Kosoy MY, Saito EK, Green D, Marston EL, Jones DC, Childs JE (2000) Experimental evidence of host specificity of *Bartonella* infection in rodents. *Comp Immunol Microbiol Infect Dis* 23:221–238
26. Kumar S, Tamura K, Nei M (2004) MEGA3: Integrated software for Molecular Evolutionary Genetics Analysis and sequence alignment. *Brief Bioinform* 5:150–163
27. La Scola B, Zeaiter Z, Khamis A, Raoult D (2003) Gene-sequence-based criteria for species definition in bacteriology: the *Bartonella* paradigm. *Trends Microbiol* 11:318–321
28. Markov AP, Lopyrev IV, Irkhin AI, Khliap LA, Levitskii SA, Kirillov Mlu, Manuvera VA, Il'ina TS, Pokrovskaya MS, Aleshkin GI, Bashkirov VN, Smirnov GB, Kosoi M (2006) [Wild small mammals are the reservoir hosts of the *Bartonella* genus bacteria in the south of Moscow region]. *Mol Gen Mikrobiol Viruso* 1:8–13
29. Mediannikov O, Ivanov L, Zdanovskaya N, Vysochina N, Fournier PE, Tarasevich I, Raoult D (2005) Molecular screening of *Bartonella* species in rodents from the Russian Far East. *Ann N Y Acad Sci* 1063:308–311
30. Norman AF, Regnery R, Jameson P, Greene C, Krause DC (1995) Differentiation of *Bartonella*-like isolates at the species level by PCR-restriction fragment length polymorphism in the citrate synthase gene. *J Clin Microbiol* 33:1797–1803
31. Renesto P, Gouvement J, Drancourt M, Roux V, Raoult D (2001) Use of *rpoB* gene analysis for detection and identification of *Bartonella* species. *J Clin Microbiol* 39:430–437
32. Saitou N, Nei M (1987) The neighbor-joining method: a new method for reconstructing phylogenetic trees. *Mol Biol Evol* 4:406–425
33. Tea A, Alexiou-Daniel S, Papoutsis A, Papa A, Antoniadis A (2004) *Bartonella* species isolated from rodents, Greece. *Emerg Infect Dis* 10:963–964
34. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG (1997) The CLUSTAL\_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. *Nucleic Acids Res* 25:4876–4882
35. Welch DF, Carroll KC, Hofmeister EK, Persing DH, Robison DA, Steigerwalt AG, Brenner DJ (1999) Isolation of a new subspecies, *Bartonella vinsonii* subsp. *arupensis*, from a cattle rancher: identity with isolates found in conjunction with *Borrelia burgdorferi* and *Babesia microti* among naturally infected mice. *J Clin Microbiol* 37:2598–2601
36. Ying B, Kosoy MY, Maupin GO, Tsuchiya KR, Gage KL (2002) Genetic and ecologic characteristics of *Bartonella* communities in rodents in southern China. *Am J Trop Med Hyg* 66:622–627
37. Zeaiter Z, Fournier PE, Ogata H, Raoult D (2002) Phylogenetic classification of *Bartonella* species by comparing *groEL* sequences. *Int J Syst Evol Microbiol* 52:165–171
38. Zeaiter Z, Liang Z, Raoult D (2002) Genetic classification and differentiation of *Bartonella* species based on comparison of partial *ftsZ* gene sequences. *J Clin Microbiol* 40:3641–3647

# Molecular Epidemiology of Feline and Human *Bartonella henselae* Isolates

Rim Bouchouicha, Benoit Durand, Martine Monteil, B.B. Chomel, Moez Berrich, Mardjan Arvand, Richard J. Birtles, Edward B. Breitschwerdt, Jane E. Koehler, Ricardo Maggi, Soichi Maruyama, Rick Kasten, Elisabeth Petit, Henri-Jean Boulouis, and Nadia Haddad

Multiple locus variable number tandem repeat analysis was performed on 178 *Bartonella henselae* isolates from 9 countries; 99 profiles were distributed into 2 groups. Human isolates/strains were placed into the second group. Genotype I and II isolates shared no common profile. All genotype I isolates clustered within group B. The evolutive implications are discussed.

*Bartonella henselae* is the zoonotic agent of cat-scratch disease and has been associated with bacillary angiomatosis, bacillary peliosis, endocarditis, osteomyelitis, and neuroretinitis (1). It is usually present in low numbers in infected human tissues, whereas cats, the natural reservoir for the bacterium, are prone to persistent bacteremia. Therefore, most *B. henselae* isolates are of feline origin. Two genotypes, based on 16S rDNA differences, have been described (1). Genotype I was more frequently observed in humans in some countries where most cats are infected with genotype II (2,3). Genotype II is more prevalent in cats in Europe, Australia, and the United States (2-6), and most feline isolates from Asia belong to genotype I (7-9). In a recent study, 3 (1.6%) of 191 *B. henselae* isolates harbored 2 different 16S rDNA cop-

ies and could not be assigned to a distinct genotype (10). However, most isolates harbored 2 identical 16S rDNA copies and were assigned to either type I or II, confirming that delineation of *B. henselae* isolates in two 16S rDNA types is generally reasonable.

Multiple-locus variable number tandem repeat analysis (MLVA) was recently developed for *B. henselae* typing (6). The results are produced in an intrinsically quantitative form, called a profile, corresponding to the number of basic units in an isolate for each variable number tandem repeat (VNTR). MLVA was more discriminatory (11) than the other widely used typing techniques, such as pulsed-field gel electrophoresis (2), multilocus sequence typing (MLST) (12) and multispacer typing (MST) (13). In our protocol, MLVA involves the amplification of 5 main VNTR loci, BHV-A to -E, for *B. henselae* VNTRs (6).

## The Study

We analyzed 178 *B. henselae* isolates/strains from various sources (Table 1): 156 (88%) feline isolates/strains, 21 (11%) from diseased humans, and 1 isolate from a sick dog. The number of alleles varied from 7 (BHV-E) to 22 (BHV-B). Most of the European isolates (all but 1 of feline origin) (2,4,6) and of the American isolates/strains (North Carolina and California) (5,14), of which 85% were of feline origin, belonged to genotype II (89% and 64.6%, respectively). The Asian isolates (all but 1 of feline origin) (7-9) and the Australasian isolates (60% of human origin) (12), mainly belonged to genotype I (89.6% and 65%, respectively).

Ninety-nine different MLVA profiles were observed (Table 1), corresponding to an average number of isolates per profile of 1.8 (Table 2). Sixty-nine of these profiles were found in only 1 isolate or strain (67%), and 30 were observed in >1 isolate. Among these, none was shared by genotype I and genotype II isolates. Diversity index (DI) was 0.98 (Table 1). Diversity was observed in both genotypes because genotype-specific DIs were almost identical (Table 1).

MLVA profiles appeared location-specific because only 4 (13%) of the 30 profiles observed in >1 isolate/strain were present in >1 continent (Table 2). Within continents, no marked dominance of a given profile was observed, and continent-specific DIs were similar (Table 1).

Of the 99 *B. henselae* profiles, 12 were obtained from the 21 human isolates/strains and 1 from the dog, whereas 92 profiles were obtained from the 156 feline isolates. Five profiles were common to 5 human and 11 feline isolates. Among the 30 profiles observed in  $\geq 2$  isolates, 23 were observed only in feline isolates (Table 2). The proportion of genotype I profiles was significantly higher in human-specific profiles than in cat-specific profiles ( $p = 0.01$ , by Fisher test).

Author affiliations: Ecole Nationale Vétérinaire d'Alfort, Maisons Alfort, France (R. Bouchouicha, M. Monteil, M. Berrich, E. Petit, H.-J. Boulouis, N. Haddad); Agence Française de Sécurité Sanitaire des Aliments, Maisons Alfort (B. Durand); University of California, Davis, California, USA (B. Chomel, R. Kasten); Zentrum für Gesundheitsschutz, Dillenburg, Germany (M. Arvand); University of Liverpool, Cheshire, UK (R.J. Birtles); North Carolina State University, Raleigh, North Carolina, USA (E. Breitschwerdt, R. Maggi); University of California, San Francisco, California, USA (J. Koehler); and Nihon University, Kanagawa, Japan (S. Maruyama)

DOI: 10.3201/eid1505.080995

Table 1. Description of *Bartonella henselae* isolates and strains tested, global diversity of the typing system, and diversity variations according to 16S rDNA genotype, continent, and host\*

Characteristics	No. isolates/ strains	No. profiles	Average no. isolates/profiles	DI	No. alleles (minimum–maximum no. repeats)				
					A	B	C	D	E
All <i>B. henselae</i>	178	99	1.8	0.98	8 (9–16)	22 (5–37)	14 (1–25)	8 (1–9)	7 (1–7)
16S rDNA genotype I	64	44	1.5	0.98	6	12	11	6	6
16S rDNA genotype II	114	55	2.0	0.97	6	15	7	7	6
Location									
Europe	80†	42	1.9	0.95	6	12	6	6	5
Asia	29‡	22	1.3	0.98	7	10	8	4	3
USA	49§	28	1.7	0.95	4	12	7	6	6
Australia–New Zealand	20¶	11	1.8	0.87	4	5	5	4	6
Host									
Human + dog	22#	12	1.8	0.87	2	6	6	3	6
Healthy cat	156	92	1.7	0.98	8	20	11	8	7

\*DI, diversity index; A, BHV-A; B, BHV-B; C, BHV-C; D, BHV-D; E, BHV-E.

†Denmark, 18 (7); France, 23 (7); Germany, 27 (2); UK, 12 (5).

‡Japan, 12 (8); Philippines, 7 (9); Thailand, 10 (10).

§California: 36, including 5 owners and their 11 cats (6, 14); North Carolina, 12 (provided by Ed Breitschwerdt). Reference strain Houston 1.

¶Australia, 18 and New Zealand, 2 (3, 12).

#21 human isolates from 1 German patient with bacillary angiomatosis (BA) (2), 1 Japanese patient with cat-scratch disease (provided by S. Maruyama), 12 Australian human patients with cat-scratch disease (3), 5 California human patients with BA (14), 1 North Carolina patient with a wide range of symptoms, including fatigue, joint pain, insomnia, headache, blurred vision, irritability (provided by Ed Breitschwerdt), plus the reference strain Houston 1 (ATCC 49882, initially isolated from a patient with BA) (3), and 1 isolate from a dog with endocarditis (provided by Ed Breitschwerdt).

For BHV-A, only 2 alleles (14 and 15 copies) were found in isolates from humans, whereas all 8 identified alleles were observed in cat isolates. The number of repeats differed significantly between sick humans and healthy cats ( $p = 0.02$ , by Fisher test).

Relationships between the 99 MLVA profiles were analyzed by unweighted pair group method with arithmetic mean (UPGMA), using a categorical distance, with a *B. koehlerae* isolate used as an outgroup. To take into account that UPGMA is sensitive to taxa entry order, we computed the majority-rule consensus tree of 500 dendrograms built with random taxa entry order. MLVA profiles were grouped into 2 main groups named A and B (online Appendix Figure, available from [www.cdc.gov/EID/content/15/5/813.htm](http://www.cdc.gov/EID/content/15/5/813.htm)). Group A (26 profiles), was exclusively constituted by genotype II feline isolates. Group B (73 profiles), to which all human isolates belonged, further divided in 2 subgroups, Ba and Bb. Subgroup Ba (38 profiles) was exclusively composed of genotype I isolates, including the reference strain Houston I and a homogenous subgroup, Ba1, containing 84% of the Asian isolates. Finally, 83% of subgroup Bb isolates belonged to genotype II (29/35 profiles).

The utility of MLVA for molecular epidemiologic analysis of clusters was tested using isolates from California cats and their owners (14). Five human–cat groups of *B. henselae* isolates were analyzed. For 1 cat–human pair of isolates, which belonged, respectively, to genotype II and genotype I, major profile differences were observed, as expected. The 4 other cat–human groups, which possessed the same genotype, also had the same MLVA profile with the 5 tested BHV, as well as with the 6 additional BHV (F–K)

and variant alleles for BHV-A and/or B (6). Sequencing confirmed these results.

## Conclusions

Our results confirm that VNTRs are excellent molecular markers for confirming or excluding the responsibility of a given cat in the transmission of *B. henselae* to a human. In California, the profile identity observed within 4 clusters further supports the hypothesis that all these humans acquired infection from their respective domestic cat contacts.

MLVA enabled a clear separation between genotypes I and II, because no profile was shared between both genotypes. The dendrogram showed a high level of discrimination between 16S rDNA genotypes in the *B. henselae* population tested. Interestingly, the groups and subgroups delineated by MLVA were the same as those defined by MLST, a standard method for phylogenetic analysis (12). The same was observed with MST (13). The isolates of the subgroup Bb appeared divergent and distant from each other and from subgroup Ba that contains almost all genotype I profiles (98%). Moreover and despite possible clustering for some of the isolates, none of the 21 human isolates was present in group A. Interestingly, as for most of the human patients, the isolate obtained from the ill dog also belonged to genotype I.

These observations suggest that all genotype I isolates could be phylogenetically derived from genotype II isolates located in group B but not in group A, as already suggested using MLST (15). This observation could mean that genotype II isolates belonging to group B are closer to genotype I isolates than to genotype II isolates belonging to group